Haemophilus influenzae type B conjugate vaccine - Tianjin CanSino Biotechnology
Latest Information Update: 08 Nov 2024
Price :
$50 *
At a glance
- Originator Tianjin CanSino Biotechnology
- Class Conjugate vaccines; Haemophilus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haemophilus infections
Most Recent Events
- 01 Oct 2024 Preclinical trials in Haemophilus infections (Prevention) in China (IM) prior to October 2024
- 01 Oct 2024 CanSino Biologics plans a phase I trial for Haemophilus infections (Prevention, In infants, In adolescents, In children, In adults) in unknown location (IM, Injection) (NCT06621654)